EDITAS MEDICINE
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.
EDITAS MEDICINE
Industry:
Biotechnology Genetics Health Care Medical
Founded:
2013-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.editasmedicine.com
Total Employee:
101+
Status:
Active
Contact:
(617) 401-9000
Total Funding:
656.6 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Nginx Sitelinks Search Box
Similar Organizations
Recombinetics
Recombinetics targets biomedical and regenerative medicine, opening vast new opportunities to improve and extend human life.
Ring Therapeutics
Ring Therapeutics company focused on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy.
Nabsys
Nabsys is a life sciences company focused on the development of solid-state, single-molecule positional sequencing technology.
AOBiome
AOBiome is a life sciences company that focuses on transforming human health.
NiKang Therapeutics
NiKang Therapeutics is a biotech company focused on discovering and developing small molecule oncology medicines.
Veritas Genetics
Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Vaxess Technologies
Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.
Verve Therapeutics
Verve Therapeutics is a genetic medicine firm that is developing treatments for cardiovascular disease.
Merus
Merus is a biomedical company engaged in the discovery and development of antibody-based biopharmaceuticals.
Metamark Genetics
Metamark Genetics develops prognostic and predictive diagnostic tests that enable personalized treatment planning for cancer patients.
Viridian Therapeutics
Viridian Therapeutics is a biotechnology company that offers treatments for patients suffering from diseases.
Medicinal Genomics
Medicinal Genomics is pioneering the genomics of medical cannabis and hemp.
MicuRx Pharmaceuticals
MicuRx discovers and develops novel antibiotics to prevent and treat drug-resistant bacterial infections.
Mainstay Medical
Mainstay Medical is a global medical device company that is developing devices to deliver innovative therapies.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Avrobio
Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Aquyre Biosciences
Aquyre Biosciences provides tissue adequacy assessment thru tissue micro-architecture delineation and intracellular data acquisition.
Amunix
Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics.
Ambys Medicines
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies.
Alpine Immune Sciences
Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.
Alector
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
EdiGene
EdiGene is a biotechnology company that develops genome editing technologies.
ExThera Medical
ExThera Medical Corporation is developing revolutionary medical.
Evolve Biosystems
Evolve Biosystems specializes in providing microbiome-based products designed to develop, restore, and maintain.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Exuma Biotech
EXUMA Biotech is a clinical-stage biotechnology company that focuses on discovering and developing CAR-T cell products for solid tumors.
Emedgene
Emedgene provides data-driven AI solutions for genomic diagnostics and discovery at scale.
EGenesis
EGenesis focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs.
Evelo Biosciences
Evelo Biosciences is dedicated to improving the lives of patients globally through the development of monoclonal microbials.
Berry Genomics
Berry Genomics is a company specializing in developing and commercializing technologies for life sciences and clinical applications.
Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
BIND Therapeutics
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics.
BG Medicine
BG Medicine is a life sciences company developing biomarker-based diagnostic tests for the cardiovascular sectors.
Bionano Genomics
BioNano Genomics develops nanoscale imaging and analytic platforms designed to analyze DNA and other genome-related peptides and proteins.
Blue Water Vaccines
Blue Water Vaccines is a company developing a universal flu vaccine based on technology.
Flame Biosciences
Flame Biosciences develops value-added medicines in the emerging area of inflammasome science.
Foundation Medicine
Foundation medicine is a molecular information company developing clinical diagnostic tests that facilitates personalized cancer therapies.
QuantuMDx Group
QuantuMDx is a medical devices company developing handheld and portable diagnostic, genomic sequencing, and proteomic platforms.
Quartet Medicine
Quartet Medicine is discovering and developing novel treatments
Claritas Pharmaceuticals
Claritas Pharmaceuticals is pioneering the development of a next generation of cannabinoid therapeutics.
Kytopen
Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
10X Genomics
10X Genomics ELV solutions and security systems company that provides an innovative genomics platform.
ShouTi
ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR.
Senseonics
Senseonics is a medical device startup company that focuses on the design, development, and commercialization of glucose monitoring systems.
Sun Genomics
Sun Genomics provides personalized probiotic solutions based on AI and whole-genome sequencing of the microbiome.
Singlera Genomics
Singlera Genomics is a fast growing company focusing on non-invasive genetic testing.
Strand Life Sciences
Strand is leading a new generation of healthcare defined by genetic insights into disease.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Kintara Therapeutics
Kintara Therapeutics is engaged in developing and commercializing therapies for the treatment of cancer patients.
Homology Medicines
Homology Medicines is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases.
HelixNano
Helix Nanotechnologies uses artificial intelligence to help cure genetic diseases.
Impact Biomedicines
Impact Biomedicines is pioneering the development of life-changing treatments for patients.
Inivata
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis.
Intellia Therapeutics
Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
GeneMatters
GeneMatters delivers genetic counseling services for hospitals, health networks, academic research centers, and genetic testing labs.
Genocea Biosciences
Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies.
Generate Biomedicines
Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.
GigaGen
GigaGen specialized in the early discovery and development of recombinant biotherapeutic medicines.
Galena Biopharma
Galena Biopharma, Inc. is focused on discovering, developing and commercializing innovative therapies.
Fabric Genomics (formerly Omicia)
Global healthcare platform for genomics-driven precision medicine. Fabric' proven AI algorithms power genomic insights.
Clade Therapeutics
Clade Therapeutics discovers and delivers next-generation cell medicines to improve the lives of patients.
Cydan
Cydan is an orphan drug accelerator focused on identifying and de-risking compounds with therapeutic and commercial potential.
Cleveland BioLabs
Cleveland BioLabs is a clinical-stage biotech developing a robust pipeline of drugs for multiple medical and defense applications.
Celsius Therapeutics
Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.
Centerline Biomedical
Centerline Biomedical, a Cleveland Clinic spin-off, is developing an innovative system
Chroma Medicine
Chroma Medicine is a new genomic medicine company working on epigenetic editing.
Astria Therapeutics
Astria Therapeutics discovers and develops innovative drugs for treating inflammatory conditions.
Constellation Pharmaceuticals
Constellation Pharmaceuticals develops drugs in the field of epigenetics focusing on selective regulators of its function.
Penn Medicine
Penn Medicine is the medical school of the University of Pennsylvania that provides medical research and education services.
Prime Medicine
Prime Medicine operates as a biotechnology company that delivers the promise of gene editing using Prime Editing.
Praxis Precision Medicines
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Pharmazz
Pharmazz is a Biopharmaceutical Company.
Current Advisors List
Board_member
2017-05-01
Board_member
Board_member
Board_member
Current Employees Featured
Charlene Stern Executive Vice President & General Counsel @ Editas Medicine
Executive Vice President & General Counsel
2019-10-01
Kevin Bitterman Interim President @ Editas Medicine
Interim President
Mark S.Shearman Chief Scientific Officer & Executive Vice-President @ Editas Medicine
Chief Scientific Officer & Executive Vice-President
2021-06-01
Michelle Robertson Chief Financial Officer @ Editas Medicine
Chief Financial Officer
Clare Carmichael Chief Human Resources Officer @ Editas Medicine
Chief Human Resources Officer
2020-04-01
Charles Albright Executive Vice President and Chief Scientific Officer @ Editas Medicine
Executive Vice President and Chief Scientific Officer
2016-08-01
John Follit Associate Director - iPSC Engineering @ Editas Medicine
Associate Director - iPSC Engineering
2020-01-01
Rene Myers Sr. Director Clinical Science @ Editas Medicine
Sr. Director Clinical Science
2020-09-01
Chris Wilson Vice President, Lead Discovery @ Editas Medicine
Vice President, Lead Discovery
2021-01-01
Cynthia Collins President & Chief Executive Officer @ Editas Medicine
President & Chief Executive Officer
2019-08-01
Founder
Stock Details
Investors List
Khosla Ventures
Khosla Ventures investment in Series B - Editas Medicine
Omega Funds
Omega Funds investment in Series B - Editas Medicine
Boris Nikolic
Boris Nikolic investment in Series B - Editas Medicine
Third Rock Ventures
Third Rock Ventures investment in Series B - Editas Medicine
Jennison Associates
Jennison Associates investment in Series B - Editas Medicine
Polaris Partners
Polaris Partners investment in Series B - Editas Medicine
GV
GV investment in Series B - Editas Medicine
EcoR1 Capital
EcoR1 Capital investment in Series B - Editas Medicine
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - Editas Medicine
T. Rowe Price
T. Rowe Price investment in Series B - Editas Medicine
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-18 | Editas Appoints "Hardcore Clinician-Scientist" Baisong Mei as CMO |
| 2022-06-06 | Editas Medicine Reports Inducement Grants to New Chief Executive Officer |
| 2022-04-14 | Editas Medicine Appoints Gilmore O’Neill as Chief Executive Officer |
Official Site Inspections
http://www.editasmedicine.com Semrush global rank: 1.34 M Semrush visits lastest month: 21.64 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Editas Medicine"
Editas Medicine
What if we could repair broken genes? That is the question we ask ourselves at Editas Medicine. At Editas Medicine, our mission and commitment is to harness the power and potential of …See details»
Editas Medicine - Wikipedia
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures; the name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual proper…See details»
Editas Company Profile | Management and Employees List
Www.editasmedicine.com Editas Profile and History Editas Medicine is a genome editing company focused on translating the power and potential of genome editing systems into a pipeline of …See details»
Research and Pipeline - Editas Medicine
In Vivo Gene Edited Medicines . We are pursuing a number of diseases using an in vivo editing approach, focusing on hematopoietic stem cells, liver, and other tissue types, and we are excited about the progress we’ve made.. Blood …See details»
Editas Medicine - Crunchbase Company Profile
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome …See details»
Committee Composition - Editas Medicine
Organization, Leadership and Compensation Committee; Jessica Hopfield, Ph.D. Independent Director: Audit Committee: Nominating and Corporate Governance Committee: Bernadette …See details»
Overview | Editas Medicine
Feb 24, 2025 Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in MarchSee details»
Editas Medicine - LinkedIn
Editas Medicine | 47,721 followers on LinkedIn. What If You Could Repair Broken Genes? | What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine.See details»
Media & Investors - ir.editasmedicine.com
Dec 12, 2024 Focus on in vivo CRISPR-edited medicines based on Editas researchers’ recent scientific progress in multiple tissues:. Achieved pre-clinical in vivo proof of concept of high …See details»
Editas Medicine - Craft
Oct 29, 2024 Editas Medicine has 5 employees across 3 locations and $32.31 m in annual revenue in FY 2024. See insights on Editas Medicine including office locations, competitors, …See details»
Editas Medicine - VentureRadar
"Our mission is to translate the power and potential of CRISPR gene editing into a broad class of medicines that can transform lives. We have focused our research and development efforts on …See details»
Editas Medicine, Inc. - Cruelty Free Investing
Editas Medicine, Inc. engages in the development and commercialization of genome editting technology. Its technology includes clustered, regularly interspaced short palindromic repeats …See details»
Editas Medicine Strengthens Executive Leadership Team with …
CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda …See details»
Editas Medicine 2025 Company Profile: Stock Performance
Editas Medicine General Information Description. Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat …See details»
Editas Medicine Inc - Company Profile - GlobalData
Website www.editasmedicine.com Telephone 1 617 4019000. No of Employees 246. Industry Pharmaceuticals and Healthcare. Ticker Symbol & Exchange EDIT (NASD) Revenue (2024) …See details»
Newsroom - Editas Medicine
Dec 12, 2024 Access the latest press releases and other information from Editas Medicine, a leading gene editing company dedicated to developing CRISPR medicines for people living …See details»
Editas Medicine Regains Full Global Rights to Ocular Medicines
Aug 6, 2020 Enhances strategic flexibility and control of lead programs, including EDIT-101. CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: …See details»
Editas Medicine Announces Chief Financial Officer Transition
Mar 20, 2025 --Editas Medicine, Inc., a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, …See details»
Editas Medicine Announces Fourth Quarter and Full Year 2020 …
Feb 25, 2021 To access the call, please dial (844) 348-3801 (domestic) or (213) 358-0955 (international) and provide the passcode 7172199. A live webcast of the call will be available …See details»
Information for Patients - Editas Medicine
Oct 18, 2023 The Editas Medicine Commitment. Engage regularly – seek out opportunities to learn from the communities we aim to create a treatment option for, and continue to bring their …See details»